MSH6 and neoplasm: Despite the increased sensitivity of the NCL_MSI assay in the Manchester cohort, it could not reliably identify tumours with inherited pathogenic MMR mutations, particularly cases with isolated MSH6 loss by IHC, classifying six out of eleven as MSS (Table 3).